Related Experiment Video
Updated: May 1, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma
Joshua Zhu1,2, Maria Tsoli1,2, Jean Bertoldo1,2
1School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Kensington, New South Wales, Australia.
Abstract:
Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with a 1%-2% overall survival, largely due to the ineffectiveness of conventional treatments such as chemotherapy and radiotherapy, as well as the inoperability of the tumors because of their critical location and infiltrative diffuse growth. Recent advances in targeted therapies offer new hope, particularly those addressing key molecular characteristics and newly identified cancer dependencies. Among these are histone deacetylase inhibitors (HDACis), receptor tyrosine kinase inhibitors, and novel agents such as ONC201 and unesbulin that target metabolic and epigenetic pathways respectively. In addition, emerging therapies like FACT inhibitors and polyamine pathway inhibitors are showing promise by disrupting critical cancer cell processes. Immunotherapies, including CAR-T cells targeting surface antigens such as GD2 and B7-H3, cancer vaccines, monoclonal antibodies, and oncolytic viruses, are also gaining traction, offering a new approach by harnessing the immune system to attack tumor cells. Despite these advances, challenges such as drug delivery across the blood-brain barrier and therapeutic resistance persist, necessitating the development of combination therapies and innovative delivery methods. Ongoing research is focused on refining these strategies and exploring additional molecular and immunological targets to improve outcomes for children with DMG.
Insights
Diffuse midline glioma (DMG) is a rare pediatric brain cancer with poor survival. Novel targeted therapies and immunotherapies show promise, but challenges remain for effective treatment.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Therapeutics
Background:
- Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with a very low survival rate.
- Conventional treatments like chemotherapy and radiotherapy are largely ineffective for DMG.
- Tumor location and infiltrative growth make surgical removal difficult.
Purpose of the Study:
- To review recent advances in targeted therapies and immunotherapies for diffuse midline glioma.
- To highlight novel agents and emerging treatment strategies for pediatric brain tumors.
- To discuss challenges and future directions in DMG treatment.
Main Methods:
- Review of recent scientific literature on diffuse midline glioma treatments.
- Analysis of targeted therapy agents including HDAC inhibitors, RTK inhibitors, ONC201, unesbulin, FACT inhibitors, and polyamine pathway inhibitors.
- Evaluation of immunotherapeutic approaches such as CAR-T cells, cancer vaccines, monoclonal antibodies, and oncolytic viruses.
Main Results:
- Targeted therapies are emerging, focusing on molecular characteristics and cancer dependencies.
- Novel agents like ONC201 and unesbulin target metabolic and epigenetic pathways.
- Immunotherapies, including CAR-T cells, offer a new strategy by engaging the immune system.
Conclusions:
- Despite advances, significant challenges like drug delivery across the blood-brain barrier and therapeutic resistance persist.
- Combination therapies and innovative delivery methods are crucial for improving outcomes.
- Ongoing research into molecular and immunological targets is vital for advancing DMG treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...